Erratum: Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1 (Mol Pharmacol (2015) 87 (150-161) DOI: 10.1124/mol.114.095380);Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-Overexpressing breast cancer cells via Src-focal adhesion kinase and Forkhead box protein M1

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 150-161

  Sanabria Figueroa, Eduardo ^a,b   Donnelly, Siobhan M ^a   Foy, Kevin C ^b,d   Buss, Meghan C ^a,c   Castellino, Robert C ^a,c   Paplomata, Elisavet ^a   Taliaferro Smith, Latonia ^a   Kaumaya, Pravin T P ^d   Nahta, Rita ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; FORKHEAD BOX PROTEIN M1; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR ANTIBODY; PROTEIN; PROTEIN KINASE P60; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; FOCAL ADHESION KINASE 1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; PTK2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ONCOGENE SRC; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FOCAL ADHESION KINASE 1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, SRC; HUMANS; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84919714378     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/MOL.114.095380ERR     Document Type: Erratum

References (51)

1. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, and Garnier J et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267.
2. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, and Elvin P et al. (2010) Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16:4876-4883.
3. Bektas N, Haaf At, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, Knüchel R, and Dahl E (2008) Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 8:42.
4. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, and HauptmannM et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402.
5. Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, Bruyneel E, Van Roy F, Garrouste F, Pommier G, and André F (2008) Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer 122:572-582.
6. Carr JR, Park HJ, Wang Z, Kiefer MM, and Raychaudhuri P (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70:5054-5063.
7. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, and Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289.
8. Chakraborty AK, Liang K, and DiGiovanna MP (2008) Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 68:1538-1545.
9. Clynes RA, Towers TL, Presta LG, and Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446.
10. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, and Lieberman G et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
11. Desgrosellier JS and Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
12. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, and Parry G (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122:685-697.
13. Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, and Pandiella A (2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 19:1860-1869.
14. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, and Fritsche HA et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808.
15. Falcioni R, Antonini A, Nisticò P, Di Stefano S, Crescenzi M, Natali PG, and Sacchi A (1997) Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 236:76-85.
16. Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, and Kaumaya PTP (2014) IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells in vitro and in vivo and combined therapy with HER-1 and HER-2 peptides induces effective anti-tumor effects. Oncoimmunology DOI: 10.4161/ 21624011.2014.956005 [published ahead of print]
17. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, and Gojis O et al. (2009) FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol 35:57-68.
18. Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, and Giner D et al. (2012) Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367-1373.
19. Gayle SS, Castellino RC, Buss MC, and Nahta R (2013) MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Curr Med Chem 20 :2486-2499.
20. Han S, Meng Y, Tong Q, Li G, Zhang X, Chen Y, Hu S, Zheng L, Tan W, and Li H et al. (2014) The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs 6:403-408.
21. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, and Lesnikoski BA et al. (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207.
22. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, and Liu B (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70:1204-1214.
23. Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, and Leyland-Jones B (2006) Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66:7245-7252.
24. Joshi JP, Brown NE, Griner SE, and Nahta R (2011) Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol 82:1090-1099.
25. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, and Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440.
26. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, and Balint CR et al. (2009) Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 27:5270-5277.
27. Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF, and Zielinski CC (2006) Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol 132: 9-18.
28. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, and Abdulkarim B (2009) Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 69:8620-8628.
29. Lu Y, Zi X, Zhao Y, Mascarenhas D, and Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857.
30. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, and Nguyen NT et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127.
31. Nahta R (2012) Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012:428062.
32. Nahta R, Yu D, Hung MC, Hortobagyi GN, and Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280.
33. Nahta R, Yuan LX, Zhang B, Kobayashi R, and Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128.
34. PeiróOrtiz-Martínez G, Gallardo F, Pérez-Balaguer A, Sánchez-Payá A, Ponce J, Tibau JJ, and L Aópez-Vilaro L, Escuin D, and Adrover E et al. (2014) Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer 111:689-695.
35. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, and Akslen LA et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-752.
36. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, and Arteaga CL (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919.
37. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, and Baba HA (2005) High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/ neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 7: R194-R203.
38. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, and Currie V et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595.
39. Siegel R, Ma J, Zou Z, and Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64 :9-29.
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, and Pegram M et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
42. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, and Bacus SS (2004) The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91:1190-1194.
43. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, and Isola J (2004) Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3:1585-1592.
44. Vadlamudi RK, Sahin AA, Adam L, Wang RA, and Kumar R (2003) Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 543:76-80.
45. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, and Ménard S et al. (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67: 11991-11999.
46. Vellon L, Menendez JA, and Lupu R (2005) AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 24: 3759-3773.
47. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, and Arteaga CL (2009) Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69:475-482.
48. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, and Hemler ME (2010) Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70:2256-2263.
49. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, and Kennecke H (2012) Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 132:131-142.
50. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, and Ding Z et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469.
51. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Mur-aoka-Cook R, Arteaga C, and Chen J (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70:299-308.